Renalytix Says US Patent Office Has Issued New Notice Of Allowance Of Claims Surrounding Biomarkers sTNFR1 And sTNFR2 Used In kidneyintelX.dkd Test
Portfolio Pulse from Benzinga Newsdesk
Renalytix has announced that the US Patent Office has issued a new notice of allowance of claims surrounding biomarkers sTNFR1 and sTNFR2 used in its kidneyintelX.dkd test.
October 06, 2023 | 11:33 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The issuance of a new notice of allowance by the US Patent Office for Renalytix's biomarkers used in its kidneyintelX.dkd test could potentially strengthen the company's intellectual property portfolio and competitive position.
The new patent allowance for Renalytix's biomarkers used in its kidneyintelX.dkd test could potentially enhance the company's intellectual property rights, providing it with a competitive edge in the market. This could lead to increased investor confidence and potentially a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100